Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat ...
With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.
As the global demand for obesity treatments skyrockets, Vikrant Shrotriya discusses the complex nature of obesity, the ...
In this regard Novo Nordisk is leading the way. We've become increasingly committed to chronic conditions that include cardiovascular disease and chronic kidney disease – the reason being ...
head of development at Novo Nordisk, noted that hypertension is a leading risk factor for cardiovascular events, heart failure, chronic kidney disease, and premature death. “With its expected ...
Research suggests potential health benefits beyond what popular diabetes and weight-loss drugs were first approved to treat.
Recent research throws into question whether GLP-1 drugs increase the risk of certain types of thyroid cancer.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback